Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

[at noodls] – Abbott Park, Illinois P(NYSE: ABT) – Abbott today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of HUMIRA® (adalimumab). … more

View todays social media effects on ABT

View the latest stocks trending across Twitter. Click to view dashboard